A Single Arm, Prospective, Multicenter, Phase II Study to Evaluate the Efficacy and Safety of Niraparib Combined With Oral Etoposide in Platinum Resistant/ Refractory Recurrent Ovarian Cancer
Latest Information Update: 26 Nov 2024
At a glance
- Drugs Etoposide (Primary) ; Niraparib (Primary)
- Indications Fallopian tube cancer; Ovarian cancer; Peritoneal cancer
- Focus Therapeutic Use
Most Recent Events
- 04 Nov 2024 Results assessing the efficacy and safety of oral niraparib plus etoposide in platinum resistant/refractory ovarian cancer in published at the International Journal of Gynecological Cancer.
- 27 Aug 2021 Planned number of patients changed from 35 to 36.
- 24 Dec 2020 Planned End Date changed from 1 Jan 2022 to 1 Jun 2022.